Evolving concepts in clostridium difficile colitis

Current Gastroenterology Reports

Volumn 11, Issue 5, 2009, Pages 400-405

  Diggs, Naomi G ^a   Surawicz, Christina M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GLUTAMATE DEHYDROGENASE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOLEVAMER; VANCOMYCIN;

AGE; ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; ENTERITIS; ENZYME IMMUNOASSAY; FECES ANALYSIS; GENETIC STRAIN; HUMAN; INFECTION PREVENTION; IRRITABLE COLON; LOW DRUG DOSE; NONHUMAN; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; REVIEW; RISK FACTOR; TISSUE CULTURE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS INFECTION; DRUG THERAPY, COMBINATION; HUMANS; INCIDENCE; IRRITABLE BOWEL SYNDROME; PROBIOTICS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WASHINGTON;

EID: 70349509724     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0060-0     Document Type: Review

References (49)

1. Voth DE, Ballard JD: CloMtridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18:247-263.
2. McDonald LC, Owings M, Jernigan JB: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-415.
3. Warmy M, Pepin J, Fang A, et al.: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
4. Loo VG, Poirier L, Miller MA, et al.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
5. Centers for Disease Control and Prevention (CDC): Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1201-1205.
6. Dial S, Abbas K, Dascal A, et al.: Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008, 179:767-772.
7. Owens RC Jr, Donskey CJ, Gaynes RP, et al.: Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S19-S31.
8. Pépin J, Saheb N, Coulombe MA, et al.: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
9. Issa M, Vijayapal A, Graham MB, et al.: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
10. Rodemann JF, Dubberke ER, Reske KA, et al.: Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
11. Kyne L, Warny M, Quamar A, et al.: Asymptomatic carriage of Clostridium difficile and serum levels of antibody against toxin A. N Engl J Med 2000, 342:390-397.
12. Leonard J, Marshall JK, Moayyedi P: Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2056.
13. Fenner L, Widmer AF, Goy G, et al.: Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008, 46:328-330.
14. Peterson LR, Manson RU, Paule SM, et al.: Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis 2007, 45:1152-1160.
15. Sharp SE, Ivie WM, Buckles MR, et al.: A simple 3-step algorithm for improved laboratory detection of Clostridium difficile toxin without the need for tissue culture cytotoxicity neutralization assays. Diagn Microbiol Infect Dis 2009, 64:344-346.
16. Debast SB, van Kregten E, Oskam KM, et al.: Effect on diagnostic yield of repeated stool testing during outbreaks of Clostridium difficile-associated disease. Clin Microbiol Infect 2008, 14:622-624.
17. Nemat H, Khan R, Ashraf M, et al.: Diagnostic value of repeated enzyme immunoassays in Clostridium difficile infection. Am J Gastroenterol, 2009, doi: 10.1038/ajg.2009.174 (Epub ahead of print).
18. Issa M, Ananthakrishnan A, Binion D: Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1432-1442.
19. Pepin J, Valiquette L, Alary ME, et al.: Clostridium difficile-associated diarrhea in a region of Quebec from 1991-2003: A changing pattern of disease severity. CMAJ 2004, 171:466-472.
20. Kuijpers EJ, van Cissel JT, Wilcox MH: Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Disease 2007, 20:376-383.
21. Hubert B, Loo VG, Bourgault AM, et al.: A portrait of the geographic dissemination of the Clostridium difficile North American pulse-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007, 44:238-244.
22. Pepin J, Alary ME, Valiquette L, et al.: Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40:1591-1597.
23. Geric B, Carman RJ, Rupnik M, et al.: Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006, 193:1143-1150.
24. McDonald LC, Killgore GE, Thompson A, et al.: An epidemic, toxin-gene variant strain of Clostridium difficile. N Engl J Med 2005, 353:503-524.
25. Muto CA, Pokrywka M, Shutt K, et al.: A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
26. Meyer AM, Ramzan NN, Loftus EV Jr, et al.: The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004, 38:772-775.
27. Ananthakrishnan AN, McGinley EL, Binion DG: Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
28. Nelson R: Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007, 3:CD004610.
29. Musher DM, Aslam S, Logan N, et al.: Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40:1586-1590.
30. Fernandez A, Anand G, Friedenberg F: Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004, 38:414-418.
31. Hu MY, Maroo S, Kyne L, et al.: A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hepatol 2008, 6:1354-1360.
32. Zar FA, Bakkanagari SR, Moorthi KM, et al.: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
33. Maroo S, Lamont JT: Recurrent Clostridium difficile. Gastroenterology 2006, 130:1311-1316.
34. McFarland LV, Tlmer GW, Surawicz CM: Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroentol 2002, 97:1769-1775.
35. Kyne L, Warny M, Quama A, et al.: Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
36. Pillai A, Nelson RL: Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008, CD004611.
37. McFarland LV, Surawicz CM, Greenberg RN, et al.: A randomized, placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
38. Surawicz CM, McFarland LV, Greenberg RN, et al.: The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin with Saccharomyces boulardii. CID 2000, 31:1012-1017.
39. Lawrence SJ, Korzenik JR, Mundy LM: Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005, 54:906.
40. Wullt M, Hägslatt ML, Odenholt I: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A double-blind, placebo-controlled trial. Scand J Infect Dis 2003, 35:365-367.
41. Jaber MR, Olafsson S, Fung WL, Reeves ME: Clinical review of management of fulminant Clostridium difficile infection. Am J Gastroenterol 2008, 103:3195-3203.
42. Bartlett JG: New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 2009, 11:21-28.
43. Louie TJ, Gerson M, Grimard D, et al.: Results of a phase III study comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD). Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: ASM Press; 2007. Abstract K-4259.
44. O'Horo J, Safdar N: The role of immunoglobulin for the treatment of Clostridium difficile infection: A systematic review. Int J Infect Dis 2009 (Epub ahead of print).
45. Sougioultzis S, Kyne L, Drudy D, et al.: Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005, 128:764-770.
46. Gerding DN, Muto CA, Owens RC Jr: Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S43-S49.
47. Sawmore MH, Venkataraman L, DeGirolami PC, et al.: Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996, 100:32-40.
48. Mayfield JL, Leet T, Miller J, Mundy LM: Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000, 31:995-1000.
49. Dellit TH, Owens RC, McGowan JE Jr, et al.: IDSA/SHEA guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.